Evaluation of clinical usefulness of HPV-16 and HPV-18 genotyping for cervical cancer screening
Journal of Gynecologic Oncology · 2024
DOI: 10.3802/jgo.2024.35.e72 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2024. Verfasst von Eun Hye Cho und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Human papillomavirus 18, Uterine Cervical Neoplasms, Human papillomavirus 16, Papillomavirus Infections. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NRF, National Research Foundation of Korea.
Abstract (Originalsprache)
OBJECTIVE: High-risk human papillomavirus (HR-HPV) infection is a leading cause of cervical cancer, of which human papillomavirus (HPV)-16 and HPV-18 account for about 70% of cases. Since HPV infection is common, it is important to focus on the HPV genotypes that pose the highest risk for effective cervical cancer screening. In this study, we evaluated the clinical usefulness of HPV-16/HPV-18 genotyping for cervical cancer screening. METHODS: A total of 86,022 women aged 25 years or older was analyzed in this study. Sensitivity, specificity, positive predictive value, and negative predictive value of HPV genotyping and cytology were analyzed. In addition, we subdivided participants into two groups according to cytology results, negative for intraepithelial lesion of malignancy (NILM) and atypical squamous cells of undetermined significance (ASC-US), and analyzed absolute risk (AR) and relative risk (RR) of cervical intraepithelial neoplasia (CIN) 3 or worse according to HPV genotype. RESULTS: The AR of CIN 3 or worse was 77.0 times higher in HR-HPV-positive compared to HR-HPV-negative. Compared to 12 other HR-HPV-positive, the AR of CIN 3 or worse was 4.2 times higher in HPV-16 and/or HPV-18 positive. This finding was more evident in women with NILM than in women with ASC-US. The RR of CIN 3 or worse was 7.0 in women with NILM and 4.5 in women with ASC-US. CONCLUSION: Regardless of the cytology results, the risk of CIN 3 or worse was higher in HPV-16/HPV-18 than in other HR-HPV. HPV-16/HPV-18 genotyping is recommended to screen women with a high risk of cervical cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Department of Laboratory Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea. mjkkmd@gmail.com.
ORCID-Profile: Eun Hye Cho, Min-Seung Park, Hee-Yeon Woo, Hyosoon Park, Min-Jung Kwon
Förderung
- NRF
- National Research Foundation of Korea
Zitieren
APA
Cho, E. H., Park, M. S., Woo, H. Y., Park, H., & Kwon, M. J. (2024). Evaluation of clinical usefulness of HPV-16 and HPV-18 genotyping for cervical cancer screening. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2024.35.e72
Vancouver
Cho EH, Park MS, Woo HY, Park H, Kwon MJ. Evaluation of clinical usefulness of HPV-16 and HPV-18 genotyping for cervical cancer screening. Journal of Gynecologic Oncology. 2024. doi:10.3802/jgo.2024.35.e72
BibTeX
@article{Cho2024,
author = {Cho, Eun Hye and Park, Min-Seung and Woo, Hee-Yeon and Park, Hyosoon and Kwon, Min-Jung},
title = {Evaluation of clinical usefulness of HPV-16 and HPV-18 genotyping for cervical cancer screening},
journal = {Journal of Gynecologic Oncology},
year = {2024},
doi = {10.3802/jgo.2024.35.e72}
}
EUVIMED